Alamar Biosciences says Emory study identifies ALS blood signature with 98.3% balanced accuracy
ALMR•Alamar Biosciences said Emory University researchers identified a 10-protein blood signature for ALS with 98.3% balanced accuracy using its NULISA technology. The research-stage signature outperformed neurofilament light chain alone, but is not a clinically validated diagnostic test.
1. Research findings
Emory University researchers identified a 10-protein blood signature for ALS using Alamar Biosciences’ NULISA technology, with 98.3% balanced accuracy. The results, published in Nature Communications, outperformed neurofilament light chain alone, identifying some patients missed by that marker while reducing false positives. The findings are not a clinically validated diagnostic test, and researchers plan to test the signature in larger, more diverse patient groups.
